
COMPASS Pathways (CMPS) Stock Forecast & Price Target
COMPASS Pathways (CMPS) Analyst Ratings
Bulls say
Compass Pathways PLC is positioned favorably in the mental health care market due to its innovative approach to psilocybin therapy for treatment-resistant depression, as demonstrated by its proprietary formulation, COMP360, which shows superior efficacy compared to existing therapies like Spravato. The company’s promising phase 2b data indicates the potential for substantial market success, particularly with estimates suggesting a significant commercial opportunity driven by broader momentum in psychedelic treatments and supportive government initiatives for mental health. Furthermore, the anticipated durability of therapeutic response, coupled with reduced inpatient treatment experiences, enhances the attractiveness of COMP360 as a viable treatment option, indicating strong potential for revenue growth.
Bears say
Compass Pathways PLC is subject to significant risk regarding the potential failure of its COMP360 psilocybin therapy and other pipeline programs in clinical trials, which could negatively impact stock performance. The recent adverse outcomes associated with Lykos Therapeutics—including a negative advisory committee vote and a Complete Response Letter (CRL)—suggest a heightened scrutiny from regulatory bodies that may affect broader acceptance and approval of psychedelic therapies, including those proposed by Compass Pathways. Additionally, sustained response rates reported for competing therapies indicate that achieving clinically meaningful efficacy may be increasingly challenging, further complicating Compass Pathways's positioning in the market.
This aggregate rating is based on analysts' research of COMPASS Pathways and is not a guaranteed prediction by Public.com or investment advice.
COMPASS Pathways (CMPS) Analyst Forecast & Price Prediction
Start investing in COMPASS Pathways (CMPS)
Order type
Buy in
Order amount
Est. shares
0 shares